Wanbang Pharmaceutical (301520.SZ) announced first-half results. Net profit to mother was 138,000 yuan, a year-on-year decrease of 99.49%

According to the Zhitong Finance App, Wanbang Pharmaceutical (301520.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 87.7577 million yuan, a year-on-year decrease of 40.24%. Net profit attributable to shareholders of listed companies was 138,000 yuan, a year-on-year decrease of 99.49%. Net loss of $134.309 million after deducting non-recurring profit and loss attributable to shareholders of listed companies.

In the context of clinical value-oriented R&D, the company continues to promote business structure optimization and accelerate its deployment into innovative drug R&D services based on technical accumulation and project experience in the fields of pharmaceutical research, clinical research and registration services. During the reporting period, the company completed the acquisition of 75.52% of Sidesheng's shares, further improving the business chain of innovative drug clinical trial operations, registration declarations, and independent third party inspections.